BLSM BlossomHill Therapeutics, Inc.

CIK 0001839970 3 ready 8-Ks latest September 18, 2026, 7:15 AM ET RSS · JSON

Activity: ELEVATED 2 filings / 30d vs 0 baseline

Ready 8-Ks 3

Latest filing September 18, 2026, 7:15 AM ET

Top materiality 0.80

Event mix other_material ×2 · earnings ×1

Sentiment 3 pos · 0 neg · 0 neu

Recent 8-K filings for BLSM

Highest-materiality recent filing

BlossomHill reports 45% ORR for BH-30643 in EGFR C797S-positive NSCLC from SOLARA trial

September 15, 2026, 7:30 AM ET other material materiality 0.80 positive item 7.01 item 9.01

ORR 45% (18/40) and DCR 88% (35/40) in EGFR C797S-positive NSCLC patients with prior EGFR inhibitor resistance, ± T790M.
63% (25/40) remained on treatment at median follow-up 6.9 months; 98% had prior osimertinib, 35% concurrent T790M.

September 18, 2026, 7:15 AM ET earnings materiality 0.65 positive item 2.02 item 9.01

BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug

Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.
September 15, 2026, 7:30 AM ET other material materiality 0.80 positive item 7.01 item 9.01

BlossomHill reports 45% ORR for BH-30643 in EGFR C797S-positive NSCLC from SOLARA trial

ORR 45% (18/40) and DCR 88% (35/40) in EGFR C797S-positive NSCLC patients with prior EGFR inhibitor resistance, ± T790M.
August 10, 2026, 4:01 PM ET other material materiality 0.80 positive item 5.03 item 8.01 item 9.01

BlossomHill Therapeutics completes IPO of 9.375M shares at $16.00, gross proceeds ~$150M

IPO closed Aug 10, 2026; 9,375,000 shares sold at $16.00 per share.

Max materiality 0.80 · Median 0.80 · Most common event other_material

3 positive 0 negative 0 neutral